A Review of Fabry Disease.
A Review of Fabry Disease. Skin Therapy Lett. 2018 May;23(3):5-9 Authors: Cinats A, Heck E Abstract The class of medications known as Janus kinase inhibitors block cytokine-mediated signaling via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, which plays an important role in immunoregulation and normal cell growth. This class includes the drugs tofacitinib, approved for the treatment of rheumatoid arthritis, and ruxolitinib, approved for the treatment of myelofibrosis and polycythemia rubra vera. The most common adverse events (AEs) reported in patients taking tofacitinib are infections, whereas the most common AEs in patients taking ruxolitinib are anemia and thrombocytopenia. Both first and second generation Janus kinase inhibitors have become promising treatment modalities for dermatologic conditions such as psoriasis, atopic dermatitis, alopecia areata, vilitigo, dermatomyositis, and graft-versus-host disease. Future promising areas of investigation include treatment of cutaneous lupus, cutaneous T-cell lymphoma, melanoma, allergic contact dermatitis, and lichen planus. PMID: 29772037 [PubMed - in process]
Publication date: Available online 16 November 2019Source: European Journal of Surgical OncologyAuthor(s): D. Moreno-Ramírez, R. Vieira, R. Kaufmann
Publication date: Available online 17 November 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Pelin Şenel, Soykan Agar, V. Oyku Sayin, Filiz Altay, Mine Yurtsever, Ayşegül GölcüAbstractFludarabine is a purine derivative, anti-neoplastic drug and is still being used in the treatments of chronic lymphocytic leukemia, small lymphocytic lymphoma, acute myeloid leukemia, Non-Hodgkin’s lymphoma. It achieves its function by interacting with DNA. Therefore, the binding interactions of such drugs with deoxyribonucleic acid (DNA) is an important subject for pharmaceutical and biochemic...
Publication date: Available online 17 November 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Sumit Kumar Hira, Kheyanath Mitra, Prateek Srivastava, Shikha Singh, Sambhav Vishwakarma, Ranjeet Singh, Biswajit Ray, Partha Pratim MannaAbstractA novel ABA-type polyethylene glycol (PEG)-b-polyketal (PK)-b-PEG block copolymer was synthesized via click reactions between the monoazido-monomethoxy-PEG and dialkyne terminated aliphatic polyketal with no carboxylic/amide linkages. Formation of the novel block copolymer was confirmed by 1H NMR, GPC, TGA and DSC studies. The formed copolymer has shown faster d...
Publication date: Available online 16 November 2019Source: Progress in Neuro-Psychopharmacology and Biological PsychiatryAuthor(s): Mijung Yeom, Sora Ahn, Ju-Young Oh, Song-Yi Kim, Hyangsook Lee, Dae-Hyun Hahm, Hi-Joon ParkAbstractClinically, it has been reported that atopic dermatitis (AD) has been linked with negative emotional problems such as depression and anxiety, thereby reducing the quality of life, but little is known about the molecular mechanism that underlies AD-associated emotional impairments. We sought to determine whether AD could induce anxiety- and depressive-like symptoms in mice and to identify pertinen...
A 56-year-old automobile mechanic was referred to our rheumatology service by his orthopedist to evaluate left posterior knee pain and swelling that had been present for three months. The patient had undergone bilateral total knee arthroplasties (TKAs) for sports-related osteoarthritis three years before. In addition to the knee pain, the patient described several years of... [Read More]
In this report, we present the case of... [Read More]
(Natural News) Lyme disease and rheumatoid arthritis are two different diseases that share many symptoms. A patient will benefit from knowing how to tell them apart. The diseases have different origins. Lyme disease is a bacterial disease caused by the bacteria Borrelia burgdorferi, which infect humans via tick bites. Meanwhile, rheumatoid arthritis stems from a mixture of...
Conclusion: ARL is a heterogeneous disease. Histologic subtype is a major determinant of the clinical outcome. ADL has significantly lower CD4 counts than those of NADL. There is an urgent and unmet need for uniform management guidelines for improving outcomes in this under-represented patient population. PMID: 31730692 [PubMed]
Conclusion: This study provides insight into the clinical presentation and treatment outcomes among patients with cHL in Malaysia. A longer study duration is required to identify OS and PFS benefits and treatment-related complications for different chemotherapeutic regimens. PMID: 31730690 [PubMed]
Authors: Ito K, Nishiyama R, Hirano K, Yamada K, Sekiguchi N PMID: 31730686 [PubMed]
More News: Allergy & Immunology | Alopecia | Alopecia Areata | Anemia | Arthritis | Cutaneous T cell lymphoma | Dermatitis | Dermatology | Dermatomyositis | Lichen Planus | Lupus | Lymphoma | Melanoma | Psoriasis | Rheumatoid Arthritis | Rheumatology | Skin | Skin Cancer | Skin Graft | T-cell Lymphoma | Thrombocytopenia